{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:42:13Z","timestamp":1792680133353,"version":"4.5.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see as their ultimate clinical potential. In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neurotoxicity while retaining potent oncolytic activity. The envelope glycoprotein (G) of VSV was replaced with a variant glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GP), creating a replicating therapeutic, rVSV(GP), that is benign in normal brain but can effectively eliminate brain cancer in multiple preclinical tumor models in vivo. Furthermore, it can be safely administered systemically to mice and displays greater potency against a spectrum of human cancer cell lines than current OV candidates. Remarkably, rVSV(GP) escapes humoral immunity, thus, for the first time, allowing repeated systemic OV application without loss of therapeutic efficacy. Taken together, rVSV(GP) offers a considerably improved OV platform that lacks several of the major drawbacks that have limited the clinical potential of this technology to date. Cancer Res; 74(13); 3567\u201378. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-3306","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T05:58:11Z","timestamp":1399615091000},"page":"3567-3578","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency"],"prefix":"10.1158","volume":"74","author":[{"given":"Alexander","family":"Muik","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Georg-Speyer-Haus, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawton J.","family":"Stubbert","sequence":"additional","affiliation":[{"name":"2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza Z.","family":"Jahedi","sequence":"additional","affiliation":[{"name":"4Department of Biomedicine, University of Bergen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Gei\u03b2","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Georg-Speyer-Haus, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[{"name":"6Institute for Virology, Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dold","sequence":"additional","affiliation":[{"name":"6Institute for Virology, Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Tober","sequence":"additional","affiliation":[{"name":"6Institute for Virology, Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Volk","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Georg-Speyer-Haus, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Klein","sequence":"additional","affiliation":[{"name":"2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Georg-Speyer-Haus, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beta","family":"Yadollahi","sequence":"additional","affiliation":[{"name":"3Apoptosis Research Centre, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Falls","sequence":"additional","affiliation":[{"name":"2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Miletic","sequence":"additional","affiliation":[{"name":"4Department of Biomedicine, University of Bergen;"},{"name":"5Department of Pathology, Haukeland University Hospital, Bergen, Norway; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stojdl","sequence":"additional","affiliation":[{"name":"3Apoptosis Research Centre, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Bell","sequence":"additional","affiliation":[{"name":"2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"6Institute for Virology, Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,6,30]]},"reference":[{"key":"2022061703502355100_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-1-60327-492-0_14","article-title":"Epidemiology of brain tumors","volume":"472","author":"Ohgaki","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2022061703502355100_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"2022061703502355100_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cytogfr.2010.04.001","article-title":"Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil","volume":"21","author":"Zemp","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022061703502355100_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotech"},{"key":"2022061703502355100_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2004.08.039","article-title":"Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses","volume":"330","author":"Ahmed","year":"2004","journal-title":"Virology"},{"key":"2022061703502355100_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2009.10.086","article-title":"Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models","volume":"116","author":"Capo-chichi","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2022061703502355100_bib7","first-page":"3605","article-title":"Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats","volume":"63","author":"Ebert","year":"2003","journal-title":"Cancer Res"},{"key":"2022061703502355100_bib8","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1523\/JNEUROSCI.4905-07.2008","article-title":"Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain","volume":"28","author":"Ozduman","year":"2008","journal-title":"J Neurosci"},{"key":"2022061703502355100_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"2022061703502355100_bib10","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1158\/0008-5472.CAN-08-0238","article-title":"Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer","volume":"68","author":"Hadaschik","year":"2008","journal-title":"Cancer Res"},{"key":"2022061703502355100_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061703502355100_bib12","first-page":"1364","article-title":"Fields virology","author":"Lyles","year":"2006","edition":"5th ed"},{"key":"2022061703502355100_bib13","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"J Gen Virol"},{"key":"2022061703502355100_bib14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/JVI.76.3.1309-1327.2002","article-title":"Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein","volume":"76","author":"van den Pol","year":"2002","journal-title":"J Virol"},{"key":"2022061703502355100_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"key":"2022061703502355100_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4269\/ajtmh.1988.39.312","article-title":"A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection","volume":"39","author":"Quiroz","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"2022061703502355100_bib17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1128\/JVI.01788-09","article-title":"Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting","volume":"84","author":"Kelly","year":"2010","journal-title":"J Virol"},{"key":"2022061703502355100_bib18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/mt.2008.130","article-title":"A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication","volume":"16","author":"Edge","year":"2008","journal-title":"Mol Ther"},{"key":"2022061703502355100_bib19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/hum.2011.146","article-title":"Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins","volume":"23","author":"Ayala-Breton","year":"2012","journal-title":"Hum Gene Ther"},{"key":"2022061703502355100_bib20","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J Virol"},{"key":"2022061703502355100_bib21","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J Virol"},{"key":"2022061703502355100_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"key":"2022061703502355100_bib23","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/JVI.76.3.1488-1495.2002","article-title":"Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range","volume":"76","author":"Beyer","year":"2002","journal-title":"J Virol"},{"key":"2022061703502355100_bib24","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-07-1240","article-title":"Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma","volume":"13","author":"Miletic","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061703502355100_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1089\/hum.2004.15.1091","article-title":"Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins","volume":"15","author":"Miletic","year":"2004","journal-title":"Hum Gene Ther"},{"key":"2022061703502355100_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/JVI.75.2.1061-1064.2001","article-title":"Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference","volume":"75","author":"Beyer","year":"2001","journal-title":"J Virol"},{"key":"2022061703502355100_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF03159989","article-title":"Ganglioside distribution in murine neural tumors","volume":"17","author":"Seyfried","year":"1991","journal-title":"Mol Chem Neuropathol"},{"key":"2022061703502355100_bib28","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1128\/JVI.73.8.6937-6945.1999","article-title":"Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway","volume":"73","author":"Boritz","year":"1999","journal-title":"J Virol"},{"key":"2022061703502355100_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00109-012-0863-6","article-title":"Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy","author":"Muik","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"2022061703502355100_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-61779-340-0_10","article-title":"Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains","volume":"797","author":"Diallo","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2022061703502355100_bib31","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/JVI.72.6.4650-4656.1998","article-title":"Evaluation of the Gal\u03b11-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses","volume":"72","author":"Welsh","year":"1998","journal-title":"J Virol"},{"key":"2022061703502355100_bib32","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1128\/JVI.02052-09","article-title":"Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication","volume":"84","author":"Simon","year":"2010","journal-title":"J Virol"},{"key":"2022061703502355100_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1354\/vp.40-5-512","article-title":"Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis","volume":"40","author":"Sur","year":"2003","journal-title":"Vet Pathol"},{"key":"2022061703502355100_bib34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI200422374","article-title":"Kinetics of protective antibodies are determined by the viral surface antigen","volume":"114","author":"Pinschewer","year":"2004","journal-title":"J Clin Invest"},{"key":"2022061703502355100_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4049\/jimmunol.118.1.348","article-title":"Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement","volume":"118","author":"Welsh","year":"1977","journal-title":"J Immunol"},{"key":"2022061703502355100_bib36","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.02040-09","article-title":"Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells","volume":"84","author":"Wollmann","year":"2010","journal-title":"J Virol"},{"key":"2022061703502355100_bib37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.surg.2012.09.003","article-title":"Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus","volume":"153","author":"Blackham","year":"2013","journal-title":"Surgery"},{"key":"2022061703502355100_bib38","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1128\/JVI.00723-11","article-title":"Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways","volume":"85","author":"Paglino","year":"2011","journal-title":"J Virol"},{"key":"2022061703502355100_bib39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ijc.25088","article-title":"Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death","volume":"127","author":"Zhang","year":"2009","journal-title":"Int J Cancer"},{"key":"2022061703502355100_bib40","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptor for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"PNAS"},{"key":"2022061703502355100_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/JVI.75.1.448-457.2001","article-title":"Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor \u03b1-dystroglycan correlate with viral tropism and disease kinetics","volume":"75","author":"Smelt","year":"2001","journal-title":"J Virol"},{"key":"2022061703502355100_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0306-4522(01)00092-6","article-title":"Dystroglycan distribution in adult mouse brain: a light and electron microscopy study","volume":"104","author":"Zaccaria","year":"2001","journal-title":"Neuroscience"},{"key":"2022061703502355100_bib43","doi-asserted-by":"crossref","first-page":"14282","DOI":"10.1128\/JVI.79.22.14282-14296.2005","article-title":"Posttranslational modification of \u03b1-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding","volume":"79","author":"Kunz","year":"2005","journal-title":"J Virol"},{"key":"2022061703502355100_bib44","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1523\/JNEUROSCI.3247-10.2010","article-title":"Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain","volume":"30","author":"Satz","year":"2010","journal-title":"J Neurosci"},{"key":"2022061703502355100_bib45","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res"},{"key":"2022061703502355100_bib46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4161\/cbt.5.4.2546","article-title":"Altered expression of \u03b1-dystroglycan subunit in human gliomas","volume":"5","author":"Calogero","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"2022061703502355100_bib47","doi-asserted-by":"crossref","first-page":"138ra77","DOI":"10.1126\/scitranslmed.3003578","article-title":"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients","volume":"4","author":"Adair","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022061703502355100_bib48","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"2022061703502355100_bib49","first-page":"412","article-title":"Blood compatibility of enveloped viruses","volume":"12","author":"Kueberuwa","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"2022061703502355100_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/382726a0","article-title":"Specific cytotoxic T cells eliminate B cells producing virus neutralizing antibodies","volume":"382","author":"Planz","year":"1996","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/13\/3567\/2700081\/3567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/13\/3567\/2700081\/3567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T10:52:24Z","timestamp":1716720744000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/74\/13\/3567\/592632\/Re-engineering-Vesicular-Stomatitis-Virus-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,30]]},"references-count":50,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2014,6,30]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-3306","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6505388","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6505388.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22399700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22399700.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,30]]}}}